Cited 9 times in
Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이재승 | - |
dc.contributor.author | 이혜원 | - |
dc.contributor.author | 장진원 | - |
dc.date.accessioned | 2021-04-29T16:42:02Z | - |
dc.date.available | 2021-04-29T16:42:02Z | - |
dc.date.issued | 2021-01 | - |
dc.identifier.issn | 1352-0504 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/181972 | - |
dc.description.abstract | Several prediction scores for the early detection of hepatocellular carcinoma (HCC) are available. We validated the predictive accuracy of age, albumin, sex, liver cirrhosis (AASL), RESCUE-B, PAGE-B and modified PAGE-B (mPAGE-B) scores in chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir disoproxil fumarate (TDF). Between 2007 and 2014, 3171 patients were recruited (1645, ETV; 1517, TDF). The predictive accuracy of each prediction score was assessed. The mean age of the study population (1977 men; 1194 women) was 48.8 years. Liver cirrhosis was present in 1040 (32.8%) patients. During follow-up (median, 58.2 months), 280 (8.8%) patients developed HCC; these patients were significantly older; more likely to be male; had significantly higher proportions of liver cirrhosis, hypertension and diabetes; and had significantly higher values for the four risk scores than those who did not develop HCC (all P < .05). Older age (hazard ratio [HR] = 1.048), male sex (HR = 2.142), liver cirrhosis (HR = 3.144) and prolonged prothrombin time (HR = 2.589) were independently associated with an increased risk of HCC (all P < .05), whereas a higher platelet count (HR = 0.996) was independently associated with a decreased risk of HCC (P < .05). The predictive accuracy of AASL score was the highest for 3- and 5-year HCC predictions (areas under the curve [AUCs] = 0.818 and 0.816, respectively), followed by RESCUE-B, PAGE-B and mPAGE-B scores (AUC = 0.780-0.815 and 0.769-0.814, respectively). In conclusion, four HCC prediction scores were assessed in Korean CHB patients treated with ETV or TDF. The AASL score showed the highest predictive accuracy. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Blackwell Scientific Publications | - |
dc.relation.isPartOf | JOURNAL OF VIRAL HEPATITIS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jin Won Chang | - |
dc.contributor.googleauthor | Jae Seung Lee | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Yeon Seok Seo | - |
dc.contributor.googleauthor | Han Ah Lee | - |
dc.contributor.googleauthor | Mi Na Kim | - |
dc.contributor.googleauthor | Yu Rim Lee | - |
dc.contributor.googleauthor | Seong Gyu Hwang | - |
dc.contributor.googleauthor | Kyu Sung Rim | - |
dc.contributor.googleauthor | Soon Ho Um | - |
dc.contributor.googleauthor | Won Young Tak | - |
dc.contributor.googleauthor | Young Oh Kweon | - |
dc.contributor.googleauthor | Soo Young Park | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.identifier.doi | 10.1111/jvh.13411 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A05963 | - |
dc.contributor.localId | A03318 | - |
dc.contributor.localId | A06020 | - |
dc.relation.journalcode | J01928 | - |
dc.identifier.eissn | 1365-2893 | - |
dc.identifier.pmid | 33029863 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/jvh.13411 | - |
dc.subject.keyword | antiviral therapy | - |
dc.subject.keyword | chronic hepatitis B | - |
dc.subject.keyword | entecavir | - |
dc.subject.keyword | hepatocellular carcinoma | - |
dc.subject.keyword | risk prediction score | - |
dc.subject.keyword | tenofovir disoproxil fumarate | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.contributor.affiliatedAuthor | 김범경 | - |
dc.contributor.affiliatedAuthor | 김승업 | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.contributor.affiliatedAuthor | 이재승 | - |
dc.contributor.affiliatedAuthor | 이혜원 | - |
dc.contributor.affiliatedAuthor | 장진원 | - |
dc.citation.volume | 28 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 95 | - |
dc.citation.endPage | 104 | - |
dc.identifier.bibliographicCitation | JOURNAL OF VIRAL HEPATITIS, Vol.28(1) : 95-104, 2021-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.